The earnings call reflects a positive start to 2025 with robust growth in specialty medicines and progress in the HIV segment, supported by strategic acquisitions and shareholder returns. However, challenges in vaccine sales, tariff impacts, and Medicare Part D redesign headwinds are noted, balancing the overall outlook.

Company Guidance -

Q3 2025

In the GSK Q1 2025 Results Call, the company reaffirmed its financial guidance for 2025, highlighting several key metrics. Group sales saw a 4% increase, driven by a robust 17% growth in specialty medicines. Core operating profit and core earnings per share both rose by 5%, reaching 44.9 pence. Despite a 6% decline in vaccine sales, the overall performance was in line with expectations. The company also reported cash generation from operations exceeding £1 billion, allowing further investment in growth initiatives and shareholder returns. GSK has initiated a £2 billion share buyback program and increased its dividend to 16 pence per share. Additionally, the company emphasized its commitment to innovation, with two FDA approvals secured and three more anticipated within the year. GSK's strategic focus on specialty medicines and long-acting treatments, especially in HIV and oncology, underpins its confidence in achieving sustained profitable growth, despite macroeconomic uncertainties.

Strong Sales and Profit Growth

Group sales increased by 4%, core operating profit grew by 5%, and core earnings per share rose 5% to 44.9 pence, driven by specialty medicines up 17%.

Innovation and Pipeline Progress

Two out of five expected FDA product approvals for 2025 have been secured. Notable approvals include Blenrep in the UK and expected FDA decisions for Nucala COPD and depemokimab.

HIV Treatment and Prevention Growth

HIV sales grew 7%, with strong demand for Dovato, Cabenuva, and Apretude, growing 19%, 38%, and 63% respectively.

Strategic Acquisitions and Investments

Completion of the acquisition of IDRX, and the commencement of a £2 billion share buyback program.

Sustained Dividends and Shareholder Returns

Quarterly dividend increased to 16 pence, with over £0.8 billion returned to shareholders through dividends and buybacks.

GlaxoSmithKline (GB:GSK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:GSK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.47 / -	0.497	―	―	―
Apr 30, 2025	2025 (Q1)	0.40 / 0.45	0.431	4.18% (+0.02)	―	―
Feb 05, 2025	2024 (Q4)	0.20 / 0.23	0.289	-19.72% (-0.06)	―	―
Oct 30, 2024	2024 (Q3)	0.44 / 0.50	0.504	-1.39% (>-0.01)	―	―
Jul 31, 2024	2024 (Q2)	0.38 / 0.43	0.388	11.86% (+0.05)	―	―
May 01, 2024	2024 (Q1)	0.37 / 0.43	0.37	16.49% (+0.06)	―	―
Jan 31, 2024	2023 (Q4)	0.29 / 0.29	0.258	12.02% (+0.03)	―	―
Nov 01, 2023	2023 (Q3)	0.46 / 0.50	0.469	7.46% (+0.04)	―	―
Jul 26, 2023	2023 (Q2)	0.35 / 0.39	0.347	11.82% (+0.04)	―	―
Jul 07, 2023	2025 (Q2)	0.43 / 0.47	0.434	7.14% (+0.03)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:GSK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 30, 2025	1415.15p	1466.05p	+3.60%
Feb 05, 2025	1348.58p	1451.20p	+7.61%
Oct 30, 2024	1402.84p	1359.83p	-3.07%
Jul 31, 2024	1476.79p	1447.59p	-1.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does GlaxoSmithKline plc (UK) (GB:GSK) report earnings?

GlaxoSmithKline plc (UK) (GB:GSK) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is GlaxoSmithKline plc (UK) (GB:GSK) earnings time?

GlaxoSmithKline plc (UK) (GB:GSK) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of GlaxoSmithKline plc (UK) stock?

The P/E ratio of GlaxoSmithKline is N/A.

What is GB:GSK EPS forecast?

GB:GSK EPS forecast for the fiscal quarter 2025 (Q3) is 0.47.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing